DTX3L was originally identified as a binding partner of BAL1 (PARP9/ARTD9), which is an oncogenic factor in diffuse large B-cell lymphoma (DLBCL) with a prominent immune/inflammatory infiltrate [29]. Here, PARP9 is linked to diffuse large B-cell lymphoma.